Not applicableUnknownNCT03764917What this trial is testingNGS Combined With RNAseq on Tumor Immune Escape in NSCLCWho this might be right forNon-small Cell Lung Cancer Shanghai Pulmonary Hospital, Shanghai, China 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811What this trial is testingEnsartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationWho this might be right forNon-Small Cell Lung Cancer Sun Yat-sen University 49
Early research (Phase 1)Study completedNCT03607188What this trial is testingStudy of Alkotinib in Patients With Advanced Non Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableStudy completedNCT03271554What this trial is testingTreatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in KoreaWho this might be right forNon-Small Cell Lung Cancer Hoffmann-La Roche 355
Early research (Phase 1)Active Not RecruitingNCT05681780What this trial is testingClinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCWho this might be right forNon Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer H. Lee Moffitt Cancer Center and Research Institute 13
Not applicableNot Yet RecruitingNCT06644495What this trial is testingPost-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With IruplinalkibWho this might be right forNSCLC Qilu Pharmaceutical Co., Ltd. 1,000
Testing effectiveness (Phase 2)Ended earlyNCT02846792What this trial is testingNivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerWho this might be right forALK Gene TranslocationEGFR Activating MutationRecurrent Non-Small Cell Lung Carcinoma+3 more University of Washington 5
Not applicableUnknownNCT04499794What this trial is testingThe Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic MonitoringWho this might be right forUntreated Advanced NSCLC PatientsFISH Identified ALK Fusion Positive or Negative Chinese Academy of Medical Sciences 75
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07415005What this trial is testingLorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerWho this might be right forAdvanced Non-Small Cell Lung Cancer M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Looking for participantsNCT06749886What this trial is testingAn Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line SettingWho this might be right forLung Cancer Shanghai Pulmonary Hospital, Shanghai, China 22
Early research (Phase 1)Active Not RecruitingNCT04227028What this trial is testingBrigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCWho this might be right forLocally Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+7 more City of Hope Medical Center 5
Testing effectiveness (Phase 2)Study completedNCT03535740What this trial is testingBrigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibWho this might be right forALK-positive Advanced NSCLC Ariad Pharmaceuticals 103
Testing effectiveness (Phase 2)WithdrawnNCT01500824What this trial is testingA Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Pfizer
Large-scale testing (Phase 3)Active Not RecruitingNCT02838420What this trial is testingEvaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)Who this might be right forAnaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche 187
Large-scale testing (Phase 3)Ended earlyNCT04427072What this trial is testingStudy of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationWho this might be right forCarcinoma, Non-Small-Cell Lung Novartis Pharmaceuticals 22
Not applicableUnknownNCT04317651What this trial is testingCrizotinib in ALK Rearranged Non-small-cell Lung CancerWho this might be right forNon Small Cell Lung CancerAdvanced CancerMetastatic Cancer Fondazione Ricerca Traslazionale 500
Testing effectiveness (Phase 2)Looking for participantsNCT05351320What this trial is testingWX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer (NSCLC) Jinming Yu 40
Testing effectiveness (Phase 2)Looking for participantsNCT05950139What this trial is testingPeptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLCWho this might be right forNSCLC Stage IVALK Fusion Protein Expression Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Study completedNCT04677595What this trial is testingStudy of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Novartis Pharmaceuticals 37
Not applicableLooking for participantsNCT06361589What this trial is testingReal World Study of Lolatinib for Advanced ALK+ NSCLC PatientsWho this might be right forALK-positive Non-small Cell Lung CancerReal World Study Sichuan Cancer Hospital and Research Institute 200